Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-28
2007-08-28
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S231500, C544S281000, C544S111000
Reexamination Certificate
active
10537758
ABSTRACT:
The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.
REFERENCES:
patent: 6245759 (2001-06-01), Bilodeau et al.
patent: 6380203 (2002-04-01), Bilodeau et al.
patent: 6544988 (2003-04-01), Bilodeau et al.
patent: WO-00/53605 (2000-09-01), None
Hasan et al. Expert Opin. Biol. Ther. 1(4): 703-718, 2001.
Pegram et al. Semin. Oncol. 29(3) Suppll11) 29-37, 2002.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Bruggen, N.V., et al., “VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain”, The Journal of Clinical Investigation, vol. 104, pp. 1613-1620 (1999).
Deckers, M.M.L., .et al., “Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation”, Endocrinology, vol. 141, pp. 1667-1674 (2000).
Fraley, M. E., et al., “Optimization of a Pyrazolo [1,5-alpyrimidine Class of KDR Kinase Inhibitors: Improvements in Physical Properties Enhance Cellular Activity and Pharmacokinetics”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 3537-3541 (2002).
Fraley, M.E., et al., “Property-Based Design of KDR Kinase Inhibitors”, Current Medicinal Chemistry, vol. 11, pp. 709-719 (2004).
Fraley, M.E., et al., “Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo [1,5-alpyrimidines: A New Class of KDR Kinase Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 2767-2770, (2002).
Gerber, H.P., et al., “VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation”, Nature Medicine, vol. 5, pp. 623-628 (1999).
Greenberg, D.A., et al., “Angiogenesis and Stroke”, Drug News Perspect, vol. 11, pp. 265-270 (1998).
Hasegawa, T., et al., “Intracortical osteoblastic osteosarcoma with oncogenic rickets”, Skeletal Radiology, vol. 28, pp. 41-45 (1999).
Nakagawa, M., et al., “Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts”, FEBS Letters, vol. 473, pp. 161-164 (2000).
Paul, R. et al., “Src deficiency of blockade of Src activity in mice provides cerebral protection following stroke”, Nature Medicine, vol. 7, pp. 222-227 (2001).
Rak, J., et a., “Mutant ras Oncogenes Upregulate VEGF/FPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis”, Cancer Research, vol. 55, pp. 4575-4580 (1995).
Fraley Mark E.
Hambaugh Scott R.
Hungate Randall W.
Rubino Robert S.
Balasubramanian Venkataraman
Beeler Nicole M.
Merck & Co. , Inc.
Muthard David M.
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3846791